Pharming Group NV
AEX:PHARM

Watchlist Manager
Pharming Group NV Logo
Pharming Group NV
AEX:PHARM
Watchlist
Price: 0.7355 EUR 2.65% Market Closed
Market Cap: 498.9m EUR
Have any thoughts about
Pharming Group NV?
Write Note

Intrinsic Value

The intrinsic value of one PHARM stock under the Base Case scenario is 1.0567 EUR. Compared to the current market price of 0.7355 EUR, Pharming Group NV is Undervalued by 30%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PHARM Intrinsic Value
1.0567 EUR
Undervaluation 30%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Pharming Group NV

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for PHARM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about PHARM?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Pharming Group NV

Provide an overview of the primary business activities
of Pharming Group NV.

What unique competitive advantages
does Pharming Group NV hold over its rivals?

What risks and challenges
does Pharming Group NV face in the near future?

Has there been any significant insider trading activity
in Pharming Group NV recently?

Summarize the latest earnings call
of Pharming Group NV.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Pharming Group NV.

Provide P/S
for Pharming Group NV.

Provide P/E
for Pharming Group NV.

Provide P/OCF
for Pharming Group NV.

Provide P/FCFE
for Pharming Group NV.

Provide P/B
for Pharming Group NV.

Provide EV/S
for Pharming Group NV.

Provide EV/GP
for Pharming Group NV.

Provide EV/EBITDA
for Pharming Group NV.

Provide EV/EBIT
for Pharming Group NV.

Provide EV/OCF
for Pharming Group NV.

Provide EV/FCFF
for Pharming Group NV.

Provide EV/IC
for Pharming Group NV.

Show me price targets
for Pharming Group NV made by professional analysts.

What are the Revenue projections
for Pharming Group NV?

How accurate were the past Revenue estimates
for Pharming Group NV?

What are the Net Income projections
for Pharming Group NV?

How accurate were the past Net Income estimates
for Pharming Group NV?

What are the EPS projections
for Pharming Group NV?

How accurate were the past EPS estimates
for Pharming Group NV?

What are the EBIT projections
for Pharming Group NV?

How accurate were the past EBIT estimates
for Pharming Group NV?

Compare the revenue forecasts
for Pharming Group NV with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Pharming Group NV and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Pharming Group NV against its competitors.

Analyze the profit margins
(gross, operating, and net) of Pharming Group NV compared to its peers.

Compare the P/E ratios
of Pharming Group NV against its peers.

Discuss the investment returns and shareholder value creation
comparing Pharming Group NV with its peers.

Analyze the financial leverage
of Pharming Group NV compared to its main competitors.

Show all profitability ratios
for Pharming Group NV.

Provide ROE
for Pharming Group NV.

Provide ROA
for Pharming Group NV.

Provide ROIC
for Pharming Group NV.

Provide ROCE
for Pharming Group NV.

Provide Gross Margin
for Pharming Group NV.

Provide Operating Margin
for Pharming Group NV.

Provide Net Margin
for Pharming Group NV.

Provide FCF Margin
for Pharming Group NV.

Show all solvency ratios
for Pharming Group NV.

Provide D/E Ratio
for Pharming Group NV.

Provide D/A Ratio
for Pharming Group NV.

Provide Interest Coverage Ratio
for Pharming Group NV.

Provide Altman Z-Score Ratio
for Pharming Group NV.

Provide Quick Ratio
for Pharming Group NV.

Provide Current Ratio
for Pharming Group NV.

Provide Cash Ratio
for Pharming Group NV.

What is the historical Revenue growth
over the last 5 years for Pharming Group NV?

What is the historical Net Income growth
over the last 5 years for Pharming Group NV?

What is the current Free Cash Flow
of Pharming Group NV?

Discuss the annual earnings per share (EPS)
trend over the past five years for Pharming Group NV.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Pharming Group NV

Current Assets 316.3m
Cash & Short-Term Investments 213.4m
Receivables 46.2m
Other Current Assets 56.8m
Non-Current Assets 146.5m
Long-Term Investments 10.4m
PP&E 33.5m
Intangibles 71.3m
Other Non-Current Assets 31.4m
Current Liabilities 78m
Accounts Payable 72.5m
Other Current Liabilities 5.4m
Non-Current Liabilities 166.1m
Long-Term Debt 166.1m
Efficiency

Earnings Waterfall
Pharming Group NV

Revenue
277.6m USD
Cost of Revenue
-31.8m USD
Gross Profit
245.8m USD
Operating Expenses
-262.2m USD
Operating Income
-16.5m USD
Other Expenses
3.1m USD
Net Income
-13.3m USD

Free Cash Flow Analysis
Pharming Group NV

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

PHARM Profitability Score
Profitability Due Diligence

Pharming Group NV's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
Negative Free Cash Flow
46/100
Profitability
Score

Pharming Group NV's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

PHARM Solvency Score
Solvency Due Diligence

Pharming Group NV's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Negative Net Debt
45/100
Solvency
Score

Pharming Group NV's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PHARM Price Targets Summary
Pharming Group NV

There are no price targets for PHARM.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for PHARM?

Click here to dive deeper.

Dividends

Pharming Group NV
does not pay dividends
Shareholder Yield

Current shareholder yield for PHARM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

PHARM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Pharming Group NV Logo
Pharming Group NV

Country

Netherlands

Industry

Biotechnology

Market Cap

493.6m EUR

Dividend Yield

0%

Description

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Contact

ZUID-HOLLAND
Leiden
Darwinweg 24
+31715247400.0
www.pharming.com

IPO

1998-07-02

Employees

321

Officers

President, CEO & Executive Director
Dr. Sijmen de Vries M.B.A., M.D.
Chief Financial Officer
Mr. Jeroen Wakkerman
Chief Operations Officer
Ms. Mireille Sanders M.Sc.
Investor Relations Manager
Susanne Embleton
Chief Ethics & Compliance Officer
Mr. Ruud Van Outersterp
Chief Medical Officer
Dr. Anurag Relan M.D., MPH
Show More
Chief Commercial Officer & GM Americas
Mr. Stephen Toor
Chief Business Officer
Dr. Alexander Breidenbach M.B.A.
Consultant
Dr. Bruno M. L. Giannetti
Show Less

See Also

Discover More
What is the Intrinsic Value of one PHARM stock?

The intrinsic value of one PHARM stock under the Base Case scenario is 1.0567 EUR.

Is PHARM stock undervalued or overvalued?

Compared to the current market price of 0.7355 EUR, Pharming Group NV is Undervalued by 30%.

Back to Top